A Phase 3 interventional study of Pexastimogene Devacirepvec (Pexa Vec) and Sorafenib in Hepatocellular Carcinoma (HCC), sponsored by SillaJen, Inc.. Completed at 142 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-08.
Sponsored by SillaJen, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 926 studies in Carcinoma, Hepatocellular with a site in United States — 160 open to participants now, 245 under way, 17 of them phase 3. Carcinoma, Hepatocellular · United States.
Among the 926 studies in Carcinoma, Hepatocellular with a site in United States, this one is the 67th largest by enrollment of the 775 interventional ones that give a count, is one of 36 that started in 2015, is one of 61 in phase 3, and was the 432nd registered.
3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.
Browse Carcinoma, Hepatocellular studies →160 of the 926 studies in Carcinoma, Hepatocellular with a site in United States are open now. Recruiting first, the newest first:
University of Arizona · Sites in United States
Ages 18–99
Abramson Cancer Center at Penn Medicine · Sites in United States
Ages 18+
University of Texas Southwestern Medical Center · Sites in United States
Ages 18+
University of Texas Southwestern Medical Center · Sites in United States
Ages 18+
Varian, a Siemens Healthineers Company · Sites in United States
Ages 21+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
926 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 336 · Phase 2 376 · Phase 3 66 · Phase 4 14
First in 1977; this study’s year is marked. 36 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 459 is above the median of 53 across 2,623 interventional studies indexed under Carcinoma, Hepatocellular.
Median enrollment 36 across the 775 interventional studies, 132 across the 121 observational. Of the 602 that completed or were terminated, 262 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
318 of 926 have an industry lead sponsor. The 10 most frequent:
SillaJen, Inc. is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
SillaJen, Inc. has 1 study filed under Carcinoma, Hepatocellular — fewer than ten, so there is no comparison to draw.
83 of the studies in Carcinoma, Hepatocellular with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03654053Phase 3VA Office of Research and DevelopmentMulti-Center Study of the Effects of Simvastatin on Hepatic Decompensation and Death in Subjects Presenting With High-Risk Compensated Cirrhosis | 2026-12-31 |
| NCT06109272Phase 3AbbVieA Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) | 2027-01 |
| NCT05822752AbbVieStudy to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC) | 2026-11 |
| NCT01918683Abramson Cancer Center at Penn MedicineTACE With or Without SBRT as Bridging Therapy for Pre-transplant HCC Patients | 2026-12 |
| NCT04410302University of California, DavisPatient-Derived Xenografts to Reduce Cancer Health Disparities | 2026-12 |
Add all 83 to your calendar (.ics) → With an account.
Among the 926 studies in Carcinoma, Hepatocellular with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a randomized Phase 3 study to determine whether treatment with vaccinia virus based immunotherapy (Pexa-Vec) followed by sorafenib increases survival compared to treatment with sorafenib in patients with advanced hepatocellular carcinoma who have not received prior systemic therapy.
This is a multi-center, randomized, open-label, Phase 3 study comparing Pexa Vec followed by sorafenib versus sorafenib in patients with advanced HCC without prior systemic therapy.
A total of 459 patients were randomly assigned to 2 treatment arms- 234 patients in the Pexa-Vec followed by sorafenib treatment group and 225 patients in the sorafenib only treatment group.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pexa-Vec (pexastimogene devacirepvec) will be administered as 3 bi-weekly intratumoral (IT) injections of 1e9 pfu at day 1 and weeks 2 and 4, followed by sorafenib at Week 6.
Biological: Pexastimogene Devacirepvec (Pexa Vec) · Drug: Sorafenib
Sorafenib (400 mg twice daily) begins on Day 1.
Drug: Sorafenib
Pexa-Vec is a vaccinia virus based oncolytic immunotherapy designed to stimulate the immune system following infection and replication within tumor cells.
Also known as: JX-594
Sorafenib belongs to the pharmacotherapeutic group of antineoplastic agents, protein kinase inhibitors, ATC code: L01XE05. Sorafenib is a multi-kinase inhibitor which has demonstrated both anti-proliferative and anti-angiogenic properties in vitro and in vivo. Sorafenib is approved for the treatment of advanced HCC and is the Standard Of Care for this disease.
Also known as: Nexavar
Overall Response Rate (ORR)
Percentage of participants who showed overall response during their participation in the study. Per Modified Response Evaluation Criteria In Solid Tumors Criteria (mRECIST) and assessed by tri-phasic contrast enhanced CT: Complete Response (CR), Disappearance of intratumoral enhancing area; Partial Response (PR), \>=30% decrease in the sum of the diameters of enhancing area; Overall Response (OR) = CR + PR.
Time frame: From date of randomization to the date of first documented radiographic tumor progression up to 53 months
| Milestone | Pexa-Vec Followed by Sorafenib | Sorafenib |
|---|---|---|
| Started | 234 | 225 |
| Safety population | 218 | 217 |
| Completed | 161 | 153 |
| Not completed | 73 | 72 |
Percentage of participants who showed overall response during their participation in the study. Per Modified Response Evaluation Criteria In Solid Tumors Criteria (mRECIST) and assessed by tri-phasic contrast enhanced CT: Complete Response (CR), Disappearance of intratumoral enhancing area; Partial Response (PR), \>=30% decrease in the sum of the diameters of enhancing area; Overall Response (OR) = CR + PR.
| percentage of participants | Pexa-Vec Followed by Sorafenib | Sorafenib |
|---|---|---|
| Overall Response Rate (ORR) | 19.2 | 20.9 |
Collected over From date of randomization to end of participation in the study, up to 53 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pexa-Vec Followed by Sorafenib | 33/218 (15.1%) | 117/218 (53.7%) | 218/218 (100%) |
| Sorafenib | 25/217 (11.5%) | 77/217 (35.5%) | 214/217 (98.6%) |
| Event | Pexa-Vec Followed by Sorafenib | Sorafenib |
|---|---|---|
| Hepatic failureHepatobiliary disorders | 11/218 | 8/217 |
| PyrexiaGeneral disorders | 8/218 | 1/217 |
| AscitesGastrointestinal disorders | 8/218 | 4/217 |
| Abdominal pain upperGastrointestinal disorders | 7/218 | 3/217 |
| AstheniaGeneral disorders | 3/218 | 5/217 |
| Abdominal painGastrointestinal disorders | 4/218 | 5/217 |
| Hepatic encephalopathyNervous system disorders | 5/218 | 4/217 |
| Neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 4/218 | 4/217 |
| Blood bilirubin increasedInjury, poisoning and procedural complications | 1/218 | 4/217 |
| PneumoniaInfections and infestations | 3/218 | 4/217 |
| Event | Pexa-Vec Followed by Sorafenib | Sorafenib |
|---|---|---|
| PyrexiaGeneral disorders | 184/218 | 28/217 |
| DiarrhoeaGastrointestinal disorders | 107/218 | 116/217 |
| Palmar plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 73/218 | 99/217 |
| Decreased appetiteMetabolism and nutrition disorders | 85/218 | 64/217 |
| NauseaGastrointestinal disorders | 74/218 | 63/217 |
| ChillsGeneral disorders | 71/218 | 4/217 |
| FatigueGeneral disorders | 65/218 | 64/217 |
| Abdominal painGastrointestinal disorders | 62/218 | 60/217 |
| Weight decreasedInvestigations | 58/218 | 49/217 |
| VomitingGastrointestinal disorders | 56/218 | 27/217 |
| Age, Categorical(Participants) | Pexa-Vec Followed by Sorafenib | Sorafenib | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 133 | 148 | 281 |
| >=65 years | 101 | 77 | 178 |
| Age, Continuous(years) | Pexa-Vec Followed by Sorafenib | Sorafenib | Total |
|---|---|---|---|
| Mean | 61.3 ± 10.05 | 60.5 ± 11.06 | 60.9 ± 10.55 |
| Sex: Female, Male(Participants) | Pexa-Vec Followed by Sorafenib | Sorafenib | Total |
|---|---|---|---|
| Female | 30 | 43 | 73 |
| Male | 204 | 182 | 386 |
| Ethnicity (NIH/OMB)(Participants) | Pexa-Vec Followed by Sorafenib | Sorafenib | Total |
|---|---|---|---|
| Hispanic or Latino | 5 | 6 | 11 |
| Not Hispanic or Latino | 229 | 219 | 448 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Pexa-Vec Followed by Sorafenib | Sorafenib | Total |
|---|---|---|---|
| Singapore | 8 | 3 | 11 |
| Hong Kong | 1 | 3 | 4 |
| United States | 40 | 34 | 74 |
| United Kingdom | 3 | 4 | 7 |
| Thailand | 2 | 5 | 7 |
| Portugal | 2 | 3 | 5 |
| New Zealand | 27 | 27 | 54 |
| Canada | 5 | 4 | 9 |
| South Korea | 61 | 68 | 129 |
| China | 42 | 40 | 82 |
| Taiwan | 13 | 10 | 23 |
| Italy | 1 | 3 | 4 |
| Israel | 1 | 2 | 3 |
| Australia | 9 | 5 | 14 |
| France | 12 | 8 | 20 |
| Germany | 7 | 6 | 13 |
| ECOG performance status(Participants) | Pexa-Vec Followed by Sorafenib | Sorafenib | Total |
|---|---|---|---|
| 0 | 146 | 142 | 288 |
| 1 | 88 | 83 | 171 |
Showing the first 100 of 142 sites across 16 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2015 to primary completion in Jul 2020, 57 months.
Results were first posted in Dec 2020, 5 months after primary completion.
Of 53 industry-sponsored phase 3 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 63. This study's 57 months is close to that.
Counting every sponsor, half of 139 studies reached it within 56 months; a quarter within 43 and three quarters within 83.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: JX-594